

PD PPS

PERITONEAL DIALYSIS OUTCOMES
AND PRACTICE PATTERNS STUDY

PDOPPS:

Identifying optimal practices in PD

EDTNA

Sunday 10th September, 2017

Krakow, Poland

Jennie King - on behalf of the PDOPPS team

Acknowledgments

Special thanks for PDOPPS support to:

Baxter Healthcare

Japanese Society for Peritoneal Dialysis

Canadian Institute for Health Research

National Health and Medical Research Council of Australia

**Research for Patient Benefit programme, National Institute
for Health Research, UK**

**Thailand Research Foundation, National Research Council
of Thailand, Chulalongkorn University**

**We're grateful for these organizations and their
commitment to fulfilling the mission of PDOPPS**

Arbor Research conducts the PDOPPS in close collaboration with the International Society for Peritoneal Dialysis (ISPD)



PDOPPS:

Primary and Secondary Outcomes

Primary Outcome:

- All Cause PD Technique Failure

Secondary Outcomes:

- All-cause mortality
- Cause specific PD technique failure:
 - Inadequate clearance
 - Infection-related
 - Psychosocial-related
 - Catheter-related*
 - Mechanical-related*

Secondary Outcomes:


- PD related complications:
 - Hospitalizations
 - PD-related infections
 - Residual kidney function decline/anuria
 - PD access intervention
- Patient-reported outcomes (PRO)
- Clinical/laboratory measures:
 - Peritoneal membrane function: transport Status, UF capacity
 - Metabolic/inflammatory: Lipids, HbA1C, CRP

* Will miss some early failures

Patient Enrollment

<u>Patient Enrollment Status</u>			
	Census (N)	Selected (N)	Consented (N)
United States	8002	3808	3400
Canada	3077	1295	924
Japan	1586	1005	891
Australia	1962	819	435
United Kingdom	1978	614	304
New Zealand	316	116	66
Thailand	3995	712	610
Total:	20,916	8369	6630

International PDOPPS Timeline



Facility Characteristics

Characteristic	A/NZ	Canada	Japan	Thailand	UK	US
# of facilities	17	20	26	21	18	81
Facility structure						
Facility location within a hospital	31%	69%	100%	94%	94%	2%
Facility affiliated with a university	50%	37%	35%	5%	50%	15%
PD facility age, mean years (std)	27(9)	26(13)	26(6)	10(7)	31(6)	17(11)
Physician patient ratio, median	1:9	1:20	1:9	1:100	1:33	1:8
Nurse patient ratio, median	1:11	1:16	1:6	1:50	1:9	1:17
In-center HD provided on site	41%	95%	92%	91%	89%	71%
Home HD care provided on site	88%	70%	35%	0%	78%	67%
Routine multidisciplinary review	18%	5%	62%	33%	0%	3%
Laboratory program on site	47%	40%	69%	43%	83%	77%
Percentage of nurses who care for PD patients also provide care for in-center HD patient						
None	47%	70%	8%	24%	72%	76%
<10%	29%	10%	4%	19%	22%	15%
10-60%	6%	15%	27%	24%	6%	6%
>60%	18%	5%	62%	33%	0%	3%

* Preliminary data as of February 2017

Results are shown as mean (standard deviation), %

Patient Characteristics*

PDOPPS initial cross-section of sampled patients (2014-2017)

Characteristic	ANZ	Canada	Japan	Thailand	UK	US
# of facilities	20	20	31	21	18	106
# of selected pts	320	403	623	536	182	2470
Demographics						
Male	64%	57%	63%	51%	64%	55%
Age, years						
<45	9%	13%	8%	18%	17%	19%
45-59	24%	28%	25%	38%	21%	33%
60-74	44%	39%	44%	38%	41%	35%
75+	23%	20%	23%	6%	20%	13%
BMI, kg/m ²	27.6(4.9)	27.0(5.6)	23.0(3.5)	22.6(4.1)	26.7(5.6)	28.5(6.3)
Comorbidities						
Cause of ESRD						
Diabetes	31%	36%	32%	48%	20%	36%
Glomerulonephritis	22%	21%	32%	4%	22%	13%
Other	48%	43%	35%	48%	58%	51%
CAD	32%	29%	18%	8%	29%	25%
Diabetes	44%	47%	40%	52%	28%	54%


* Preliminary data as of February 2017 among patients with baseline chart abstraction

Results are shown as mean (standard deviation), %

PD Type

PDOPPS initial cross-section of sampled patients (2014-2017)

% of Patients



N Patients: 307

380

607


529

150

555

* Preliminary data as of February 2017

of overnight changes for APD patients



* Preliminary data as of February, 2017;



PERITONEAL DIALYSIS OUTCOMES
AND PRACTICE PATTERNS STUDY


Peritonitis Treatment and Prevention Strategies: Results from the PDOPPS

Infection Prevention & Management Workgroup
Manuscript in Preparation

Neil Boudville, David Johnson, Beth Piraino, Judith Bernardini, Sharon
Nessim, Yasuhiko Ito, Graham Woodrow, Fiona Brown, John Collins,
Talerngsak Kanjanabuch, CC Szeto, Jeff Perl

Facility peritonitis rates*

Peritonitis rate (95% CI), events per patient year




* Restricted to facilities with at least 5 patient years of follow-up (n=79); US large dialysis organization facilities not included

Perl et al. ASN oral abstract (2016)

Peritonitis organism category, by country

% of peritonitis episodes



< 5% yeast in each country – combined with other/unknown


Events associated with peritonitis episodes

	A/NZ	Canada	Japan	US
Sample				
Facilities, N	14	20	27	26
Patients, N	237	723	585	736
Peritonitis episode details				
Concurrent exit site/tunnel infection	1%	6%	9%	4%
Hospitalized during peritonitis episode	64%	47%	87%	48%
PD catheter removed	15%	18%	20%	17%
Death within 90 days of diagnosis	7%	5%	4%	5%

Exit Site Antimicrobial Prophylaxis

- Exit site Mupirocin
- Exit site Polysporin
- Exit site Medihoney
- None
- Intranasal Mupirocin
- Exit site aminoglycoside
- Other

% of facilities



N facilities: 17

20

27

19


31

63

Exit Site Cleaning Strategy

- Antibacterial soap
- Non-antibacterial soap
- Chlorhexidine
- Povidone Iodine
- Sodium hypochloride
- Other


% of facilities



N facilities: 17 20 27 18 32 62

Antifungal prophylaxis during antibiotic therapy

% of facilities



Antibiotic prescription, prophylaxis, and treatment as reported by PDOPPS medical directors

	ANZ (17)	Canada (20)	Japan (28)	Thailand (19)	UK (32)	US (64)
Antibiotic prophylaxis for: (%)						
PD catheter insertion	82	100	89	90	100	64
Complicated dental procedures	59	70	68	44	34	84
Genitourinary procedures	50	35	41	39	38	54
Gynecological procedures	56	40	32	44	38	66
Lower endoscopy	59	65	36	35	66	67
Wet contamination	94	90	68	63	78	91

Preliminary data as of February 2017



PERITONEAL DIALYSIS OUTCOMES
AND PRACTICE PATTERNS STUDY


PDOPPS: Variability in Peritoneal Dialysis Patients' Training

Patient Training and Education Workgroup
Manuscript in Preparation

**Ana Figueiredo, Junhui Zhao, Brian Bieber, Judith Bernardini,
Helen Hurst, Francesca Tentori**


Typical duration of PD training

% of facilities




Typical duration of PD training sessions

% of facilities



PD training location

% of facilities



PDOPPS : predictors of early successful use

1. We are beginning to see the potential from PDOPPS
2. Wide variations are seen in peritonitis prevention and training practices (others like PD prescription and catheter insertion practices not shown)
3. Future analyses will explore the relationship between variation and outcome after making the appropriate adjustments
4. This project has enormous potential to explore issues that are important and cannot be resolved by RCTs
5. It is important to continue investment in this area of research to the benefit of the dialysis population.



THANK YOU!

Participating facility medical directors, nurses, administrators



**17th Congress of the
International Society for Peritoneal Dialysis**
VANCOUVER, CANADA | MAY 5-8, 2018